Ten of the eleven patients reported today were on low dosage and in nine there was no disease progression, the eleventh was on full dosage and tumour regressed.
Hopefully the next lot of results covering the remaining patients on full doasage will confirm disease regression, if that happens we are looking at a major re-rating of this stock.
Ann: Promising Interim Clinical Data for NOX66, page-4
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
